殷敏女士于2022年1月加入百濟神州，擔任百濟神州大中華區(qū)首席商務官。殷敏女士擁有近二十年醫(yī)藥行業(yè)從業(yè)經驗，對醫(yī)療健康領域的發(fā)展和特性有深刻的洞察。殷敏女士于2006年至2021年就職于阿斯利康，歷任高級財務規(guī)劃經理、海外區(qū)域市場戰(zhàn)略項目負責人、中國/香港合規(guī)部副總裁、商業(yè)及多元化渠道部副總裁等多個重要崗位。2018年6月，殷敏女士被委任為阿斯利康中國副總裁，腫瘤業(yè)務部負責人，并于2019年1月升任阿斯利康中國腫瘤業(yè)務部總經理。殷敏女士畢業(yè)于上海交通大學，主修金融貿易以及計算機科學，于2002年獲得中歐國際工商學院碩士學位。
Eva Yin joined BeiGene in 2022 as Chief Commercial Officer, BeiGene Greater China. Ms. Yin has nearly 20 years of experience in the pharmaceutical industry, having held various positions in finance, compliance, commercial & diversified channels, gaining insights into the development and characteristics of the healthcare industry.
Prior to BeiGene, Ms. Yin worked at AstraZeneca from 2006 to 2021, where she held various positions including Senior Business Finance Manager, Area Strategy Project Lead for International markets, Vice President of China & HK Compliance, and Vice President of Commercial & Diversified Channels. By Jan 2017, Eva expanded her responsibility to oversight of AstraZeneca HK & Macau. She was appointed AstraZeneca China Vice President, Oncology, in 2018, and promoted to General Manager of Oncology, AstraZeneca China, in 2019.
Ms. Yin graduated from Shanghai Jiao Tong University, majoring in finance & trading and computer science. She obtained her full-time MBA from CEIBS (China Europe International Business School) and completed an exchange program at London Business School in 2002.